Managed Healthcare Executive50m
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi ...
Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update
Expect Topline Phase 2 data for NDV-01 for high-grade non-muscle invasive bladder cancer (HG-NMIBC), to be presented at AUA 2025 in ...
Soleno wins FDA approval for Prader-Willi hyperphagia treatment
Soleno Therapeutics has won US Food and Drug Administration (FDA) approval for diazoxide choline – which will be branded as ...
Soleno Shares Are Up Today: What's Going On?
Soleno Therapeutics, Inc. (NASDAQ: SLNO) shares are trading higher Thursday after the company announced it secured FDA approval for its first commercial drug, Vykat XR (diazoxide choline) ...
MedPage Today3h
FDA OKs First Drug for Hyperphagia in Prader-Willi Syndrome
Diazoxide choline is the first drug indicated for hyperphagia in the rare genetic disorder. Prior to approval, people with ...
Soleno stock skyrockets on FDA drug approval
Soleno Therapeutics (SLNO) stock is skyrocketing after the company received FDA approval for its new drug to treat excessive ...
Healio6h
FDA approves first therapy to treat hyperphagia in Prader-Willi syndrome
The FDA has approved the first therapy to address hyperphagia for children and adults aged 4 years and older with Prader-Willi syndrome, Soleno Therapeutics announced. Prader-Willi syndrome is a rare ...
Fierce Pharma6h
Soleno breaks through with FDA nod for Prader-Willi syndrome treatment Vykat XR
Since 2000, when the FDA approved recombinant human growth hormone (rhGH) for those with the rare genetic disorder ...
Soleno Therapeutics execs reap stock windfall after FDA approves rare disease drug
Soleno Therapeutics' FDA-approved drug for Prader Willi Syndrome triggers executive stock bonuses as the company's value ...
STAT8h
NIH director targets misinformation research as more turmoil rocks health agencies
Under the new collaboration, OpenFold will produce a fine-tuned version of its model that’s trained on AbbVie and Johnson & ...
Stocktwits on MSN8h
Soleno Therapeutics Stock Rockets 34% Pre-Market After FDA Approves Prader-Willi Syndrome Drug: Retail Sentiment Peaks
Shares of Soleno Therapeutics (SLNO) rocketed nearly 34% in premarket trading on Thursday after the biopharmaceutical company ...
PMLive9h
FDA approves Soleno’s Vykat XR as first treatment for hyperphagia in Prader-Willi syndrome
The US Food and Drug Administration (FDA) has approved Soleno Therapeutics’ Vykat XR (diazoxide choline) extended-release ...